DUBLIN, CA— Through transformative approaches to drug development, Gilead Sciences is accelerating the delivery of innovative therapies, with George Stephen contributing to this vision in his role as Director of Global Program Management. By building and managing high-performing, cross-functional teams spanning scientific, clinical, regulatory, and commercial functions, Stephen has guided the successful delivery of critical antiviral programs from early development through regulatory approval and commercial launch. His approach centers on empowering diverse global teams to move with speed and precision when it matters most.
Stephen has channeled lessons learned from high-urgency program delivery to construct a faster and more adaptive framework for responding to future health crises. By aligning cross-functional stakeholders around shared goals and clear decision-making structures, his teams have consistently delivered complex programs on time and within scope, even under significant external pressure.
His thought leadership extends into the integration of data-driven tools and predictive analytics into program management, areas that are reshaping how pharmaceutical organizations anticipate risk and optimize development pathways. He has explored how digital innovation, including artificial intelligence and advanced analytics, can strengthen organizational resilience across the full drug development lifecycle.
A key dimension of Stephen’s work has been building productive relationships with global health authorities and international organizations to strengthen pandemic preparedness. These collaborations have supported more equitable access to life-saving treatments and enabled faster, better-coordinated responses at a global scale.
Across a broad therapeutic portfolio spanning virology, oncology, and inflammation, Stephen leads large, matrixed program teams of cross-functional experts. His focus on governance excellence, streamlined decision-making frameworks, and proactive risk management has consistently produced strong on-time delivery performance while reducing overall development cycle times.
Beyond operational leadership, Stephen is an active contributor to industry dialogue on crisis-responsive drug development and organizational agility. Through industry publications and thought leadership platforms, he shares frameworks for building pharmaceutical programs that are resilient, adaptive, and capable of responding rapidly to evolving global health challenges.
As the pharmaceutical industry continues to navigate an increasingly complex and unpredictable global health landscape, George Stephen’s work is helping define a new standard for pandemic preparedness, one built on empowered teams, intelligent systems, and coordinated global action.
Media Contact:
- George Stephen
- Independent Researcher
